Rachid Rafia

All publications

Journal articles

• Holmes GR, Ward SE, Brennan A, Bradburn M, Morgan JL, Reed MWR, Richards P, Rafia R, Wyld L, Burton M , Lifford K et al (2021) Cost-effectiveness modeling of surgery plus adjuvant endocrine therapy versus primary endocrine therapy alone in UK women aged 70 and over with early breast cancer. Value in Health. View this article in WRRO
• Harnan S, Tappenden P, Cooper K, Stevens J, Bessey A, Rafia R, Ward S, Wong R, Stein RC & Brown J (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 23(30). View this article in WRRO
• Davis S, Rafia R, Carroll C, Hamilton J & Essat M (2018) Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. Pharmacoeconomics. View this article in WRRO
• Rafia R, Pandor A, Davis S, Stevens JW, Harnan S, Clowes M, Sorour Y & Cutting R (2018) Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1143-1151. View this article in WRRO
• Scope A, Essat M, Pandor A, Rafia R, Ward S, Wyld L, Cross S & Woods H (2017) Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimens in breast cancer management: a systematic review.. International Journal of Technology Assessment in Health Care, 33(1), 32-45. View this article in WRRO
• Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2017) Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(5), 537-547. View this article in WRRO
• Kearns B, Rafia R, Leaviss J, Preston L, Brazier JE, Palmer S & Ara R (2017) The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Services Research, 17(1), 78-78. View this article in WRRO
• Rafia R, Dodd PJ, Brennan A, Meier PS, Hope VD, Ncube F, Byford S, Tie H, Metrebian N, Hellier J , Weaver T et al (2016) An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. Addiction, 111(9), 1616-1627. View this article in WRRO
• Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M & Lobo A (2016) Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 34(12), 1241-1253. View this article in WRRO
• Stevenson M, Pandor A, Martyn-St James M, Rafia R, Uttley L, Stevens J, Sanderson J, Wong R, Perkins GD, McMullan R & Dark P (2016) Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi - a systematic review and economic evaluation.. Health Technology Assessment, 20(46), 1-246. View this article in WRRO
• Rafia R, Brennan A, Madan J, Collins K, Reed MWR, Lawrence G, Robinson T, Greenberg D & Wyld L (2016) Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales. Value in Health, 19(4), 404-412.
• Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, Durrington P, Qureshi N & Wierzbicki AS (2016) Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(5), 537-547.
• Brennan A, Meier P, Purshouse R, Rafia R, Meng Y & Hill-Macmanus D (2016) Developing policy analytics for public health strategy and decisions—the Sheffield alcohol policy model framework. Annals of Operations Research, 236(1), 149-176. View this article in WRRO
• Brennan A, Meier P, Purshouse R, Rafia R, Meng Y, Hill-Macmanus D, Angus C & Holmes J (2015) The Sheffield Alcohol Policy Model - A Mathematical Description. Health Economics, 24(10), 1368-1388. View this article in WRRO
• Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P & Wyld L (2013) Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.. Health Technol Assess, 17(44), 1-302. View this article in WRRO
• Rafia R, Simpson E, Stevenson M & Papaioannou D (2013) Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.. Pharmacoeconomics, 31(6), 471-478.
• Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR, Preston LR & Meier PS (2013) Modelling the cost-effectiveness of alcohol screening and brief interventions in primary care in England.. Alcohol Alcohol, 48(2), 180-188.
• Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H & Stevens J (2012) Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.. Health Technol Assess, 16(37), 1-iv.
• Rafia R, Ara R, Packham J, Haywood KL & Healey E (2012) Healthcare costs and productivity losses directly attributable to ankylosing spondylitis.. Clin Exp Rheumatol, 30(2), 246-253.
• Ara R, Pandor A, Stevens J, Rafia R, Ward SE, Rees A, Durrington PN, Reynolds TM, Wierzbicki AS & Stevenson M (2012) Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. Eur J Prev Cardiol, 19(3), 474-483.
• Papaioannou D, Rafia R, Stevenson MD, Stevens JW & Evans P (2011) Trabectedin for the treatment of relapsed ovarian cancer.. Health Technol Assess, 15 Suppl 1, 69-75.
• Poole CD, Lebmeier M, Ara R, Rafia R & Currie CJ (2010) Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK.. Rheumatology (Oxford), 49(10), 1949-1956.
• Simpson EL, Rafia R, Stevenson MD & Papaioannou D (2010) Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.. Health Technol Assess, 14 Suppl 1, 63-67.
• Purshouse RC, Meier PS, Brennan A, Taylor KB & Rafia R (2010) Estimated effect of alcohol pricing policies on health and health economic outcomes in England: an epidemiological model.. Lancet, 375(9723), 1355-1364.
• Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.. Bone Marrow Transplant, 45(6), 1014-1021.
• Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A & Pandor A (2009) Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective.. Expert Rev Pharmacoecon Outcomes Res, 9(5), 423-433.
• Ara R, Pandor A, Stevens J, Rees A & Rafia R (2009) Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 13(34).
• Szucs TD, Largeron N, Dedes KJ, Rafia R & Bénard S (2008) Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.. Curr Med Res Opin, 24(5), 1473-1483.
• Dhont P, Trichard M, Largeron N, Rafia R & Bénard S (2008) Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium.. J Med Econ, 11(3), 431-448.
• Papaioannou D, Rafia R, Stevenson MD, Stevens JW & Evans P () Trabectedin for the treatment of relapsed ovarian cancer. Health Technology Assessment, 15(Suppl 1), 69-75.
• Simpson EL, Rafia R, Stevenson MD & Papaioannou D () Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Health Technology Assessment, 14(Suppl 1), 63-67.

Conference proceedings papers

• Mukuria CW, Brazier J & Rafia R (2015) Does the generic cancer outcome measure eortc qlq-c30 work in myelofibrosis?. Value in Health, Vol. 18(3) (pp A210-A211)
• Rafia R & Mukuria CW (2015) Exploratory Psychometric Analysis of The Eq-5d In A Myelofibrosis Population. Value in Health, Vol. 18(3) (pp A211-A211)
• Rafia R & Ward SE (2014) Approaches Used to Model the Relationship Between Progression-Free Survival (PFS) / Time-To-Progression (TTP) And Overall Survival (OS) Within Health Economic Models of Cancer Therapies. Value in Health, Vol. 17(7) (pp A557-A557)
• Rafia R, Ward SE, Scope A & Wyld L (2013) EVALUATING THE COST EFFECTIVENESS OF GENE EXPRESSION PROFILING AND IMMUNOHISTOCHEMISTRY TESTS. VALUE IN HEALTH, Vol. 16(7) (pp A413-A413)
• Rafia R, Papaioannou D, Stevenson M, Rathbone J & Woods HB (2011) EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK. VALUE IN HEALTH, Vol. 14(7) (pp A445-A445)
• Rafia R, Ara R & Lebmeier M (2010) THE COST EFFECTIVENESS OF ETANERCEPT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE UK. RHEUMATOLOGY, Vol. 49 (pp I75-I75)
• Ara R, Rafia R, Packham J, Haywood K & Healey E (2010) HEALTHCARE COSTS ALONE DO NOT DESCRIBE THE TOTAL COSTS DIRECTLY ATTRIBUTABLE TO ANKYLOSING SPONDYLITIS. RHEUMATOLOGY, Vol. 49 (pp I70-I70)

Reports

• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Appendices.
• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Part 1, Executive summary, introduction, clinical reviews and conceptual modelling.
• Kearns B, Rafia R, Leaviss J, Preston L, Wong R, Brazier J, Palmer S & Ara R (2014) Whole pathway modelling of depression in patients. (Theme 2: Mental Health). Part 2. Independent economic evaluation: methods and results, discussion and conclusion

Posters

• Mukuria C, Brazier J & Rafia R Does the generic cancer outcome measure EORTC QLQ-C30 work in Myelofibrosis? (ISPOR 20th Annual International Meeting 16-20 May 2015).
• Rafia R, Papaioannou D, Stevenson M, Rathbone J & Woods H Evaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK.
• Rafia R & Mukuria C Exploratory psychometric analysis of the EQ-5D in a Myelofibrosis population (ISPOR 20th Annual International Meeting 16-20 May 2015).